on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Approves Resolutions at Annual General Meeting
Viromed Medical AG, a leader in medical technology, held a successful virtual Annual General Meeting on July 29, 2025. Shareholders showed strong support for the company's strategic direction by approving all proposed resolutions by a significant majority. Approximately 53% of the voting share capital was represented.
CEO Uwe Perbandt highlighted the meeting's outcomes as a reinforcement of shareholder confidence. The newly authorised capital of EUR 10,125,000 aims to boost innovation and market expansion, particularly in cold plasma technology.
Additionally, Dr. Thomas Gutschlag was elected to the Supervisory Board, succeeding Dr. Jan Delphendahl. Dr. Gutschlag's expertise is expected to benefit the company's development.
The meeting also addressed corporate strategy, emphasizing innovation in cold plasma technology and international partnerships. Shareholders approved Lenzen Wirtschaftsprüfungsgesellschaft GmbH as the auditor for 2025 and endorsed several other strategic plans.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news